For immediate release:
9:01am EST, June 22, 1999
Scottsdale Scientific Signs Agreement with Bergen Brunswig Corporation (NYSE:BBC)
Agreement Initially Supplies Nine Premiere Products to Bergen Brunswig for Distribution over the Internet
Scottsdale Scientific, Inc. (Symbol: STDS), through its wholly owned subsidiary NutriCology, Inc., announced today an agreement with Bergen Brunswig Corporation
(NYSE: BBC) to supply nine of the Company?s premiere products for distribution over the Internet. In a press release dated June 14, 1999, Bergen Brunswig Corporation
(NYSE: BBC) announced a comprehensive plan to establish a revolutionary Internet offering in the electronic health care marketplace. Scottsdale Scientific is proud to be
one of the initial vendors in this endeavor. The Company was approached by Bergen Brunswig to participate in their entry into the e-commerce arena.
Marianne Sum, President and CEO of Scottsdale Scientific, states, "Since we announced our entry into the pharmacy market on January 7, 1999, we are aggressively
closing major pharmacy distribution outlets. The prior approval from Bindley Western to service their customers and this latest agreement with Bergen Brunswig to supply
our products over the Internet is evidence of our commitment to penetrate the $66 billion wholesale pharmacy arena. Furthermore, companies such as Healtheon WebMD
(Nasdaq: HLTH) and Dr. Koop.com (Nasdaq: KOOP) have experienced tremendous business success over the Internet which exemplifies the growing presence of
healthcare on the Internet. Scottsdale Scientific is excited to be one of the initial vendors to Bergen Brunswig?s (NYSE: BBC) Internet initiative."
Bergen Brunswig (NYSE: BBC) will be providing direct-to-consumer distribution of a broad range of health and beauty aids, nutraceuticals, home medical supplies,
over-the-counter and ethical healthcare products from a newly dedicated facility in Louisville, Kentucky, which will begin operations in early July. Bergen Brunswig
Corporation (NYSE: BBC), a Fortune 200 Company with annualized revenues of $17 billion, is one of the nation?s leading supply channel management companies. Bergen
Brunswig provides pharmaceuticals, medical/surgical supplies and specialty products, as well as, information management solutions and outsourcing services designed to
improve cost-effectiveness and increase value for customers across the entire health care spectrum.
Additionally, through its wholly owned subsidiary, PharMerica, Bergen serves approximately 500,000 patients in long-term care and alternate site settings. Bergen also
develops disease-specific treatment protocols and pharmacoeconomic initiatives to assist in the reduction of overall health care costs while improving disease management
and outcomes.
This agreement further opens the pharmaceutical wholesale market to Scottsdale Scientific. Clinton Abbott, Manager of the Pharmacy Market Development Division at
Scottsdale Scientific, states that "The Internet opportunity with Bergen is an excellent opportunity to establish a long-term relationship with one of the premiere
pharmaceutical wholesalers. The Bergen agreement is clearly a springboard for Scottsdale Scientific as we continue our expansion into the worldwide pharmacy arena."
Scottsdale Scientific, Inc., through its wholly owned subsidiary, NutriCology, Inc. is an innovative leader in nutraceutical research and product formulation. Since 1979, the
Company is noted for quality, hypoallergenic nutritional supplements and supplies products to approximately 6,000 physicians and health care practitioners worldwide.
Allergy Research Group was the first in the U.S. to introduce numerous specialty products including melatonin, a neurohormone, germanium sesquioxide (a trace mineral),
AntiOxtm, a broad-spectrum antioxidant, Buffered Vitamin C and the Total Nutrient Concept. (Includes all in one, proprietary formulas, Total Immunetm, Total Nervetm and
Total Hearttm)
For additional information, visit our web site at www.nutricology.com
Disclaimer: This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation,
and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether
made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the
Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
FWIW
Larry M. |
